yesterday's callIn my opinion, Baxter does not want Spectral price to pop prior to its IPO of Vantive and is calling the shots. Why would we expect otherwise? Baxter is the big whale, Spectral is the little fish.
I do not believe there is any statistical hit associated with releasing crude mortality results at 90 patients. Clearly, if this was the case, Spectral would not have gone on record a year ago that they would release these interim results.
We should all be reviewing analyst reports from Baxter to pick up on any reference to upcoming Vantive IPO and related details on PMX/EAA.